Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

National trends in alcohol pharmacotherapy: Findings from an Australian claims database
Kirsten C. Morley, Warren Logge, Sallie‐Anne Pearson, et al.
Drug and Alcohol Dependence (2016) Vol. 166, pp. 254-257
Closed Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Louisa Degenhardt, Fiona J Charlson, Alize J Ferrari, et al.
The Lancet Psychiatry (2018) Vol. 5, Iss. 12, pp. 987-1012
Open Access | Times Cited: 1236
Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys
Louisa Degenhardt, Meyer D. Glantz, Sara Evans‐Lacko, et al.
World Psychiatry (2017) Vol. 16, Iss. 3, pp. 299-307
Open Access | Times Cited: 217
Hazardous drinking and alcohol use disorders
James MacKillop, Roberta Agabio, Sarah W. Feldstein Ewing, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 93
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder
Augustin Vannier, Jessica E.S. Shay, Vladislav Fomin, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2213014-e2213014
Open Access | Times Cited: 86
Treatment rates for alcohol use disorders: a systematic review and meta‐analysis
Tesfa Mekonen, Gary Chan, Jason P. Connor, et al.
Addiction (2020) Vol. 116, Iss. 10, pp. 2617-2634
Closed Access | Times Cited: 133
Pharmacotherapeutic agents in the treatment of methamphetamine dependence
Kirsten C. Morley, Jennifer L. Cornish, Alon Faingold, et al.
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 5, pp. 563-578
Closed Access | Times Cited: 102
New Australian guidelines for the treatment of alcohol problems: an overview of recommendations
Paul Haber, Benjamin C. Riordan, Daniel T. Winter, et al.
The Medical Journal of Australia (2021) Vol. 215, Iss. S7
Closed Access | Times Cited: 69
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Anahita Rabiee, Nadim Mahmud, Caroline G. Falker, et al.
Hepatology Communications (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 36
Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial
Kirsten C. Morley, Henry R. Kranzler, Natasha Luquin, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 5, pp. 403-411
Closed Access | Times Cited: 8
Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore
ET Goh, Marsha Y. Morgan
Alimentary Pharmacology & Therapeutics (2017) Vol. 45, Iss. 7, pp. 865-882
Open Access | Times Cited: 65
New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies
Kirsten C. Morley, Christina J. Perry, Joshua Watt, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1291-1303
Closed Access | Times Cited: 32
Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone
Warren Logge, Paul Haber, Tristan Hurzeler, et al.
Psychopharmacology (2025)
Open Access
Adverse drug event profile of pharmacotherapies for alcohol use disorder: a retrospective pharmacovigilance disproportionality analysis study.
Kannan Sridharan
Expert Opinion on Drug Safety (2025), pp. 1-16
Closed Access
Antidepressants, relapse-prevention medications and both combined to reduce alcohol-related hospitalizations in individuals with severe alcohol use disorder
Patrick Bach, Johan Franck, Jonas Hällgren, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study
Patrick Bach, Johan Franck, Jonas Hällgren, et al.
Acta Psychiatrica Scandinavica (2025)
Open Access
Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study
Andrew Thompson, Darren M. Ashcroft, Lynn Owens, et al.
PLoS ONE (2017) Vol. 12, Iss. 3, pp. e0173272-e0173272
Open Access | Times Cited: 39
Alcohol addiction - the safety of available approved treatment options
Massimo Antonelli, Anna Ferrulli, Luisa Sestito, et al.
Expert Opinion on Drug Safety (2017) Vol. 17, Iss. 2, pp. 169-177
Closed Access | Times Cited: 39
Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden
Anastasia Månsson, Anna‐Karin Danielsson, Hugo Sjöqvist, et al.
Addiction Science & Clinical Practice (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
EFFICACY OF MEDICATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD): A SYSTEMATIC REVIEW AND META-ANALYSIS CONSIDERING BASELINE AUD SEVERITY
Roberta Agabio, Hugo López‐Pelayo, Pol Bruguera, et al.
Pharmacological Research (2024) Vol. 209, pp. 107454-107454
Open Access | Times Cited: 2
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence
Kirsten C. Morley, Warren Logge, Sallie‐Anne Pearson, et al.
Journal of Substance Abuse Treatment (2016) Vol. 74, pp. 23-25
Closed Access | Times Cited: 20
Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review
Susan A. Rombouts, James H. Conigrave, Richard Saitz, et al.
BMC Family Practice (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 19
The changing face of Australian data reforms: Impact on pharmacoepidemiology research
Juliana de Oliveira Costa, Claudia Bruno, Andrea L. Schaffer, et al.
International Journal for Population Data Science (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 16
Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial
Kristie Harrison, K. S. Kylie Lee, Timothy Dobbins, et al.
BMJ Open (2019) Vol. 9, Iss. 11, pp. e030909-e030909
Open Access | Times Cited: 19
Endogenous opiates and behavior: 2017
Richard J. Bodnar
Peptides (2019) Vol. 124, pp. 170223-170223
Closed Access | Times Cited: 18
Pharmacotherapy for alcohol use disorders – Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden
Sara Wallhed Finn, Andreas Lundin, Hugo Sjöqvist, et al.
Drug and Alcohol Dependence (2021) Vol. 227, pp. 108964-108964
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top